Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

415
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
415
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

135
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PDE4 inhibitor mitigates activated CD8+ T cells through NF-κB signaling in Behçet's syndrome.

Frontiers in immunology·2026
Same author

HSCT in SAVI: evidence for a curative hematopoietic approach and perspectives for gene therapy.

Molecular therapy. Advances·2026
Same author

Anifrolumab, a potential treatment for ADA2 deficiency.

RMD open·2026
Same author

SARS-CoV-2 Reinfection and Risk of Multisystem Inflammatory Syndrome in Children: A Case-Control Study.

The Pediatric infectious disease journal·2026
Same author

Belimumab use in paediatric-onset systemic lupus erythematosus: a status report in France from a retrospective multicentre descriptive study.

Rheumatology (Oxford, England)·2026
Same author

Single-cell analysis identifies CPT1a-associated metabolic remodeling in human NK cells during COVID-19.

Journal of immunology (Baltimore, Md. : 1950)·2026

Related Experiment Video

Updated: Jun 23, 2025

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.5K

How to treat monogenic SLE?

Jonathan Thuner1, Jade Cognard2, Alexandre Belot3

  • 1Internal Medicine Department, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, France; CIRI, Centre International de Recherche en Infectiologie/International Center for Infectiology Research, Université de Lyon, INSERM, Institut National de La Santé Et de La Recherche Médicale, U1111, Université Claude Bernard Lyon 1, Lyon, France.

Best Practice & Research. Clinical Rheumatology
|June 14, 2024
PubMed
Summary

Monogenic mutations offer new insights into systemic lupus erythematosus (SLE), a rare autoimmune disease. Genetic discoveries are paving the way for personalized therapies targeting SLE

Keywords:
ApoptosisEfferocytosisGene mutationMonogenic lupusPersonalized therapy self-toleranceSystemic lupus erythematosusTherapeutic interventionType-I interferonopathy

More Related Videos

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

2.9K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.4K

Related Experiment Videos

Last Updated: Jun 23, 2025

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.5K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

2.9K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.4K

Area of Science:

  • Immunology
  • Genetics
  • Rheumatology

Background:

  • Systemic lupus erythematosus (SLE) is a rare, severe autoimmune disease with unclear immunopathology.
  • Autoantibodies against double-stranded DNA are a hallmark of SLE.
  • Recent discoveries in monogenic SLE provide crucial insights into disease mechanisms.

Purpose of the Study:

  • To explore the role of genetic mutations in the pathogenesis of SLE.
  • To understand how genetic defects contribute to SLE development.
  • To discuss the translation of genetic findings into personalized therapeutic strategies for SLE.

Main Methods:

  • Genetic screening to identify key mutations in monogenic SLE.
  • Analysis of defects in apoptotic body clearance.
  • Investigation of nucleic acid sensing pathways and type-I interferon signaling.
  • Examination of B and T cell activation pathways, including TLR and NFκB signaling.

Main Results:

  • Identification of monogenic defects contributing to SLE, including impaired apoptotic clearance and aberrant nucleic acid sensing.
  • Elucidation of the role of type-I interferon pathway activation in SLE pathogenesis.
  • Understanding the breakdown of immune tolerance due to B/T cell anomalies and signaling pathway dysregulation.
  • Highlighting the link between specific genetic mutations and SLE development.

Conclusions:

  • Monogenic SLE discoveries have significantly advanced the understanding of SLE immunopathogenesis.
  • Genetic insights are crucial for developing targeted and personalized therapies for SLE patients.
  • Further research into genetic defects will continue to refine SLE treatment strategies.